S. Yousuf Zafar, MD, associate professor of medicine, Duke Cancer Institute, discusses the potential of immunotherapy for the treatment of patients with colorectal cancer (CRC).
S. Yousuf Zafar, MD
Advertisement
Articles by S. Yousuf Zafar, MD
S. Yousuf Zafar, MD, Associate Professor of Medicine at Duke Cancer Institute, discusses the potential link between low body mass index (BMI) and survival outcomes in metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Zafar on the Potential of Immunotherapy in Colorectal CancerPublished: August 31st 2015 | Updated:
Dr. Zafar on Low BMI Impact on Colorectal Cancer SurvivalPublished: July 1st 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5